Published in Medical Letter on the CDC and FDA, June 24th, 2001
He sees misdirected energy and dollars spent on litigation or circumventing intellectual property rights protections as "exceptional and unfortunate - and generally destructive in terms of drug development in [the U.S.]" He calls instead for members of industry, the Food and Drug Bar, and congressional committees to work together to carve out a fair approach...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA